Quick Heal Q2 FY27 slides: profit returns as enterprise gains

Quick Heal’s Q2 FY27 revenue rose 44.3% sequentially to INR 64.9 crore, while EBITDA swung to a INR 2.3 crore profit from a INR 17.6 crore loss in Q1; PAT was INR 5.8 crore. Year over year, revenue fell 22.3% and PAT declined 26.8%, with consumer revenue down 39.8% amid pressure from Microsoft’s free antivirus offering. Enterprise accounted for 54% of H1 FY27 revenue, and management aims to lift its share above 80% within three years, but provided no numerical financial guidance.

Analysis

Quick Heal’s rebound is not yet evidence of a durable turnaround: with year-over-year revenue still contracting, sequential profitability can reverse if enterprise deals slip or consumer demand keeps eroding. The key quality test is whether enterprise bookings convert into recognized, recurring revenue—not product launches, threat detections, or management’s stated ambition to make privacy products a major business. The reported order book and deferred revenue merit close tracking, but neither alone establishes future growth; verify renewal rates, deal conversion, and segment reconciliation, since the cited segment figures do not appear to tie to consolidated revenue.

Microsoft’s bundled Defender protection remains a structural substitute for paid consumer antivirus, limiting Quick Heal’s pricing power and making consumer stabilization a necessary offset while enterprise scales. Conversely, tighter security budgets and platform consolidation could favor vendors with credible integrated offerings, but larger enterprise accounts also bring stronger competition and potentially longer sales cycles. DPDP-related demand is a medium-term option, not yet an underwritable revenue forecast; regulatory implementation and customer budgets are catalysts, while delays or weak conversion would defer monetization.

Near term (days to weeks), the positive sequential result may support sentiment, but low-quality earnings risk remains: other income was material relative to reported profit, so assess operating profitability separately. Over 1–3 months, watch the next results for enterprise growth, order-book/deferred-revenue conversion, and repeatable EBITDA. Over 6–18 months, the consumer-to-enterprise mix shift could improve the growth profile only if new products generate renewals and cross-sell. Contrarian point: a large threat burden does not automatically translate into vendor revenue; detection statistics are not evidence of share gains or willingness to pay.

Key Decisions for Investors

• Do not chase the sequential earnings rebound. Treat Quick Heal as a watchlist/conditional long until enterprise revenue and recurring conversion improve across another reporting period; no valuation or guidance data here supports a price target.
• Set a 1–3 month alert for enterprise revenue growth, order-book and deferred-revenue trends, renewal performance, and EBITDA excluding other income. A further year-over-year contraction or failure to convert backlog would falsify the recovery thesis.
• Keep Microsoft’s free endpoint protection as a downside monitor for Quick Heal’s consumer franchise, while avoiding a direct MSFT trade on this evidence alone: the article does not quantify any material revenue or earnings impact to Microsoft.
• Treat DPDP privacy products and EDR/XDR launches as optionality, not booked growth. Upgrade conviction only on disclosed customer conversion, repeat sales, and measurable recurring revenue; regulatory delays or continued consumer declines weaken the case.